AG67 Bk. America 34

RNS Number:5725Q
IDMoS plc
30 August 2005


FOR IMMEDIATE RELEASE                                             30 AUGUST 2005





                                   IDMoS plc



  ANNOUNCES GLOBAL COLLABORATION AND COMMERCIALISATION AGREEMENT WITH DENTSPLY
                   INTERNATIONAL FOR ITS DENTAL ACTIVITIES





IDMoS plc (AIM: IDO), the specialist in disease detection and monitoring
technology, is pleased to announce that its dental subsidiary, IDMoS Dental
Systems Limited ("IDMoS" or the "Company"), has entered into a Collaboration and
Commercialisation Agreement (the "Agreement") with Dentsply International Inc.
("Dentsply"), one of the world's leading manufacturers of products for the
dental market, with operations in 120 countries. Dentsply is listed on the
NASDAQ stock market (NASDAQ-XRAY) and has a market capitalisation in excess of
$4 billion. The Company believes that this agreement provides the critical
distribution route to the market for its dental products and validates its
dental product propositions.



As part of the collaboration IDMoS has the responsibility for developing
products for the detection and monitoring of dental decay based on its
proprietary technology, and Dentsply will take the lead on marketing, sales and
promotion, including a joint clinical education plan with IDMoS, as well as
implementing regulatory strategies. The IDMoS technology has the potential to
identify dental decay, including the early reversible stages, more accurately
and with greater certainty than current alternative techniques. IDMoS is
currently commercialising the 2D application of the CMS System applying its
ACIST technology, which is on schedule to be commercially available in 2006.
This system comprises a base unit with integral analysis software and consumable
sensors.



Under the Agreement, Dentsply has exclusive global rights to promote, market and
sell current and future IDMoS dental products based on IDMoS ACIST technology.
Dentsply is also expected to participate in the development of products based on
the Company's 3D technical platform, including the 3D CMS System, to accelerate
the future commercialisation of such products. It is intended that the products
will be branded by Dentsply with IDMoS co-branding as "powered by IDMoS"
technology.



Dentsply has also committed to make financial contributions in excess of $1
million, consisting of initial payments and milestone payments expected within
the next 12 months, to support ongoing product development and marketing
activities. Dentsply has also committed substantial resources towards the
regulatory approval process and market launch of the products.



Under the agreement IDMoS will sell its products to Dentsply, and Dentsply will
then sell to the market through distribution networks. For the initial products
IDMoS has agreed the selling prices to Dentsply and for future products a
general pricing structure has been agreed.



The operation of the Agreement will be referenced to the attainment of key
performance criteria, which will be in the form of minimum numbers of installed
units. If these criteria are not achieved, the exclusivity arrangements can be
terminated by either party.



Dentsply designs, develops, manufactures and markets a broad range of products
for the dental market. It distributes its dental products under some of the most
well established brand names in the industry. In the year ended 31 December
2004, it reported revenues of approximately $1.7 billion and earnings before tax
of $274 million.



Stephen Westwood, CEO of IDMoS commented



"This is a very significant step forward in the development of IDMoS and we are
delighted to be working with Dentsply on a long term partnership basis. We
believe that its presence and expertise in the global market through its
established clinical education structure and worldwide marketing and sales
organisation, complement our capabilities in technology development and
reputation in the dental cariology market, and that this Agreement offers us the
best way to ensure that our CMS System becomes globally adopted, in a market
with an increasing emphasis on prevention rather than cure."



Gary Kunkle, Chairman and CEO of Dentsply commented



"We are delighted to have entered into this important partnership with IDMoS.
We believe that the IDMoS technology provides substantial benefits towards the
detection and monitoring of dental caries and is superior to existing technology
in the market place.   This innovation has the potential to significantly
advance the use of technology in preventive dentistry and should provide a
significant clinical advantage to dental practitioners and patients."



ENDS



For further information, please contact:
IDMoS plc
Stephen Westwood                                                   01382 598440

Buchanan Communications
Diane Stewart/Tim Anderson                                         020 7466 5000





Notes to Editors



IDMoS plc



The IDMoS business was formally established in 2001 and floated on AIM in
November 2004, raising approximately #5m via a placing.



The IDMoS CMS System was developed by two board members, Professor Nigel Pitts
and Dr Chris Longbottom. It consists of a base station, software and disposable
sensors and will have the ability to identify dental decay, including decay in
the early, reversible stages.



The Company believes that the system will provide a level of accuracy, which is
otherwise unavailable from existing commercial techniques.



In addition to satisfying an unmet clinical need, there is a global shift
towards the preventive management of dental decay and IDMoS believe that it will
be ideally positioned to take advantage of this change.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRPKCKPKBKBFFB

Bk. America 34 (LSE:AG67)
Historical Stock Chart
From Oct 2024 to Dec 2024

Bk. America 34 (LSE:AG67)
Historical Stock Chart
From Dec 2023 to Dec 2024